Sumitomo Pharma Co., Ltd.'s Form 4 filing
Roivant Sciences Ltd. (ROIV) · filed Jun 26, 2023
- Accession no.
- 0000899243-23-016487
- Filed
- Jun 26, 2023, 4:05 PM ET
- Trade date
- Jun 22, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $130.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sumitomo Pharma Co., Ltd.CIK 0001446601 | 10% Owner |
| Sumitomo Chemical Co., Ltd.CIK 0001798550 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 22, 2023 | Common Shares | SSaleDisposed | −15,116,277 | $8.60 | −$129,999,982.2 | 71,251,083 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Exhibit 24.1 - Power of Attorney (Sumitomo)